Rabaglio, M., Sun, Z., Colleoni, M., Pienkowski, T., Nogaret, J. -M., Láng, I., Smith, I., Gelber, R. D., Goldhirsch, A., Coates, A. S., Price, K. N., Castiglione-Gertsch, M., Hawle, H., Thürlimann, B., Mouridsen, H., Campone, M., Forbes, J. F., Paridaens, R. J.. Oxford University Press; 2009. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.

Viale, G., Regan, M. M., Lang, I., Thürlimann, B., Mouridsen, H., Mauriac, L., Gelber, R. D., Price, K. N., Goldhirsch, A., Gusterson, B. A., Coates, A. S., Dell'Orto, P., Mastropasqua, M. G., Maiorano, E., Rasmussen, B. B., MacGrogan, G., Forbes, J. F., Paridaens, R. J., Colleoni, M.. Oxford University Press; 2011. Which patients benefit most from adjuvant aromatase inhibitors?: results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.